What the new Brazil guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Dosing
Page 19 of 31 of this archive, newest first.
How a peptide that lasts seven days binds a receptor that recycles in minutes
A tour of what happens in the thirty seconds after binding, and why it matters at week thirty.
Seasonal use, holiday use, and the honest state of the evidence
The schedules in circulation, described accurately, with their evidentiary status attached.
The mechanism behind the mechanism
The receptor populations that produce satiety and the ones that produce nausea overlap substantially. That is why the ceiling of this drug class is where it is, and it is…
When to stop escalating and when to stop entirely
An effect is dose-limiting when it prevents adequate intake, prevents normal activity, or produces a risk of its own. Discomfort alone is not the test.
What SURPASS-4 tells us about maintenance, and what it does not
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
Spain pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
What STEP 5 tells us about maintenance, and what it does not
The commonest real-world strategy in this drug class is the least studied one.
The lowest effective dose is a real concept with almost no data behind it
Dose reduction is not withdrawal, and the trials that tested withdrawal cannot be read as testing it.
The intramuscular injection nobody intended
Skin thickness at the standard injection sites is approximately two millimetres in adults and varies remarkably little with body mass. That single finding is why short…
What the new France guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new the Netherlands guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The site you keep using is the site that stops working
Lipohypertrophic tissue is less painful to inject into, which is precisely why people keep injecting into it.
New Zealand pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
The interventions with trial support, and the much longer list without
Almost nothing in the standard management repertoire has been tested in a randomised trial in this specific population. We say what is extrapolated and from where.
Holidays, surgery, sickness: interruption in practice
Supply interruption is the commonest cause of unplanned re-titration in this market, and it is almost never framed that way.
When to stop escalating and when to stop entirely
We set out the questions that distinguish a symptom to manage from a dose to change.
What the new Nigeria guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Denmark guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Dual, triple, co-formulated: a taxonomy the coverage keeps collapsing
The glucagon arm raises energy expenditure and also raises hepatic glucose output. Balancing those is the whole engineering problem.